(Formerly the Office of the Chief Scientist and MATIMOP)
 
SEARCH
 
 
 

Check-Cap: Fast, Convenient, and Simple Colon Cancer Screening

Check-Cap developed a technology for 3D colon mapping and quick screening of malignant tumors, specifically for the early stages. “Studies show that the main reasons for avoiding the screening are the pain it entails and the unpleasant preparations,” says Lior Torem, Check-Cap’s CFO. “Our pill is the alternative for an invasive colonoscopy.”Check-cap’s pill contains a radioactive energy source and detectors, which scan the colon and transmit data to an outside receiver. The process is easy and simple, and eliminates the need for fasting and the insertion of a camera, which are required during a routine, traditional screening. Check-Cap’s need for additional knowledge and experience with the use of radioactive materials for medical applications led to the beginning of an international collaboration project with American company Lantheus.


The collaboration between Check-Cap and Lantheus means great news for the millions around the world who so far have avoided invasive colon cancer screening

Colon cancer is the second most common cause of death among cancer-related illnesses. The good news is that the discovery and removal of cell growths when they are pre-cancerous or in their early stages significantly increases the chances of preventing the disease or achieving full recovery. Check-Cap developed a technology for 3D colon mapping and quick screening of malignant tumors, specifically for these early stages. “Studies show that the main reasons for avoiding the screening are the pain it entails and the unpleasant preparations,” says Lior Torem, Check-Cap’s CFO. “Our pill is the alternative for an invasive colonoscopy.”

Check-cap’s pill contains a radioactive energy source and detectors, which scan the colon and transmit data to an outside receiver. The process is easy and simple, and eliminates the need for fasting and the insertion of a camera, which are required during a routine, traditional screening. Today, Check-Cap is the only company that offers a solution for the inconvenience, the time consuming preparations, and the dangers a colonoscopy presents. Check-Cap’s need for additional knowledge and experience with the use of radioactive materials for medical applications led to the beginning of an international collaboration project with American company Lantheus.

Logistical Network and Access to a Nuclear Reactor

“We learned of a call for proposals issued by MATIMOP and were united with the partner we needed at exactly the right time,” Says Torem.

“Lantheus was founded in the fifties and it brings to the table extensive experience in the field of radioactive medicine and access to facilities which are not available in Israel, such as a nuclear reactor for commercial purposes.”

The collaboration with Lantheus, within the framework of the first bilateral agreement with the state of Massachusetts, will aid Check-Cap in its first steps in the American market: “Lantheus has experience with obtaining the approval of regulatory bodies, such as the FDA, and a logistical distribution network which covers a majority of North America,”says Torem. And the advantages for Lantheus?

“They view the collaboration as an opportunity to enter a new field, a driving force for growth.”

“It’s a great environment,” Torem says, describing the collaboration. “The support of the Chief Scientist, an option for outside collaboration, and a display of trust in the technology given by a credible government agency, which attracts further investors.”